Aviance Capital Partners LLC Has $995,000 Position in Novo Nordisk A/S (NYSE:NVO)

Aviance Capital Partners LLC reduced its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 32.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 11,571 shares of the company’s stock after selling 5,520 shares during the period. Aviance Capital Partners LLC’s holdings in Novo Nordisk A/S were worth $995,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in NVO. Blake Schutter Theil Wealth Advisors LLC acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at about $274,000. Advisor Resource Council acquired a new position in Novo Nordisk A/S in the third quarter valued at about $247,000. Montecito Bank & Trust boosted its position in Novo Nordisk A/S by 13.8% in the third quarter. Montecito Bank & Trust now owns 3,296 shares of the company’s stock valued at $392,000 after buying an additional 400 shares in the last quarter. Consolidated Planning Corp boosted its position in Novo Nordisk A/S by 1.9% in the third quarter. Consolidated Planning Corp now owns 55,134 shares of the company’s stock valued at $6,565,000 after buying an additional 1,038 shares in the last quarter. Finally, Portside Wealth Group LLC boosted its position in Novo Nordisk A/S by 3.9% in the third quarter. Portside Wealth Group LLC now owns 59,015 shares of the company’s stock valued at $7,027,000 after buying an additional 2,200 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 1.0 %

Shares of NYSE NVO opened at $87.19 on Friday. Novo Nordisk A/S has a 1-year low of $77.82 and a 1-year high of $148.15. The company has a market cap of $391.25 billion, a PE ratio of 26.50, a P/E/G ratio of 0.90 and a beta of 0.42. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a 50-day moving average of $84.91 and a two-hundred day moving average of $105.29.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s payout ratio is 47.72%.

Analyst Ratings Changes

NVO has been the topic of a number of recent analyst reports. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.